Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion type Assertion NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_head.
- NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion description "[HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_provenance.
- NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion evidence source_evidence_literature NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_provenance.
- NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion SIO_000772 21153051 NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_provenance.
- NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion wasDerivedFrom befree-2016 NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_provenance.
- NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_assertion wasGeneratedBy ECO_0000203 NP858750.RACzYsN1t3OVj7c8t-On-zr9bDBTg3gx3gJ7WjwANC0FA130_provenance.